H2 relaxin is a biased ligand relative to H3 relaxin at the relaxin family peptide receptor 3 (RXFP3) [S]

Molecular Pharmacology

Volumn 77, Issue 5, 2010, Pages 759-772

  Van Der Westhuizen, Emma T ^a   Christopoulos, Arthur ^a   Sexton, Patrick M ^a   Wade, John D ^b   Summers, Roger J ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; FORSKOLIN; G PROTEIN COUPLED RECEPTOR; H2 RELAXIN; H3 RELAXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RELAXIN; RELAXIN 3; RELAXIN FAMILY PEPTIDE RECEPTOR 3; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BINDING COMPETITION; CELL STRAIN HEK293; CHO CELL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG BINDING SITE; DRUG RECEPTOR BINDING; ENZYME PHOSPHORYLATION; GENE ACTIVATION; HUMAN; HUMAN CELL; IC 50; INTERNALIZATION; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; REPORTER GENE; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION;

ALKALINE PHOSPHATASE; ANIMALS; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FORSKOLIN; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; MITOGEN-ACTIVATED PROTEIN KINASE 3; PLACENTA; PREGNANCY; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE; RELAXIN; SIGNAL TRANSDUCTION;

EID: 77951036184     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.061432     Document Type: Article

References (35)

1. Alessi DR, Cuenda A, Cohen P, Dudley DT, and Saltiel AR (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270:27489-27494.
2. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, and Cohen P (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408:297-315.
3. Baker JG and Hill SJ (2007) Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. Trends Pharmacol Sci 28:374-381.
4. Bathgate RA, Lin F, Hanson NF, Otvos L, Jr., Guidolin A, Giannakis C, Bastiras S, Layfield SL, Ferraro T, Ma S, Zhao C, Gundlach AL, Samuel CS, Tregear GW, and Wade JD (2006) Relaxin-3: improved synthesis strategy and demonstration of its high-affinity interaction with the relaxin receptor LGR7 both in vitro and in vivo. Biochemistry 45:1043-1053. (Pubitemid 43122269)
5. Bathgate RA, Samuel CS, Burazin TC, Layfield S, Claasz AA, Reytomas IG, Dawson NF, Zhao C, Bond C, Summers RJ, et al. (2002) Human relaxin gene 3 (H3) and the equivalent mouse relaxin (M3) gene. Novel members of the relaxin peptide family. J Biol Chem 277:1148-1157. (Pubitemid 34968862)
6. Borlongan CV, Wang Y, and Su TP (2004) Delta opioid peptide (D-Ala 2, D-Leu 5) enkephalin: linking hibernation and neuroprotection. Front Biosci 9:3392-3398.
7. Brunet A, Datta SR, and Greenberg ME (2001) Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 11:297-305. (Pubitemid 32524094)
8. Chini B and Parenti M (2004) G-protein coupled receptors in lipid rafts and caveolae: how, when and why do they go there? J Mol Endocrinol 32:325-338. (Pubitemid 38584639)
9. Davies SP, Reddy H, Caivano M, and Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95-105.
10. Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
11. Galandrin S and Bouvier M (2006) Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70:1575-1584.
12. Halls ML, Bathgate RA, and Summers RJ (2007) Comparison of signaling pathways activated by the relaxin family peptide receptors, RXFP1 and RXFP2, using reporter genes. J Pharmacol Exp Ther 320:281-290.
13. Halls ML, Bond CP, Sudo S, Kumagai J, Ferraro T, Layfield S, Bathgate RA, and Summers RJ (2005) Multiple binding sites revealed by interaction of relaxin family peptides with native and chimeric relaxin family peptide receptors 1 and 2 (LGR7 and LGR8). J Pharmacol Exp Ther 313:677-687. (Pubitemid 40604168)
14. Kamakura S, Moriguchi T, and Nishida E (1999) Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem 274:26563-26571. (Pubitemid 129520095)
15. Kenakin T (2003) Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 24:346-354.
16. Kuei C, Sutton S, Bonaventure P, Pudiak C, Shelton J, Zhu J, Nepomuceno D, Wu J, Chen J, Kamme F, et al. (2007) R3(BDelta23 27)R/I5 chimeric peptide, a selective antagonist for GPCR135 and GPCR142 over relaxin receptor LGR7: in vitro and in vivo characterization. J Biol Chem 282:25425-25435. (Pubitemid 47372825)
17. Layden SS and Tregear GW (1996) Purification and characterization of porcine prorelaxin. J Biochem Biophys Methods 31:69-80.
18. Liu C, Chen J, Kuei C, Sutton S, Nepomuceno D, Bonaventure P, and Lovenberg TW (2005) Relaxin-3/insulin-like peptide 5 chimeric peptide, a selective ligand for G protein-coupled receptor (GPCR)135 and GPCR142 over leucine-rich repeat-containing G protein-coupled receptor 7. Mol Pharmacol 67:231-240. (Pubitemid 40069983)
19. Liu C, Eriste E, Sutton S, Chen J, Roland B, Kuei C, Farmer N, Jörnvall H, Sillard R, and Lovenberg TW (2003) Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135. J Biol Chem 278: 50754-50764. (Pubitemid 37548924)
20. Marinissen MJ, Chiariello M, Pallante M, and Gutkind JS (1999) A network of mitogen-activated protein kinases links G protein-coupled receptors to the c-jun promoter: a role for c-Jun NH2-terminal kinase, p38s, and extracellular signal-regulated kinase 5. Mol Cell Biol 19:4289-4301. (Pubitemid 29242004)
21. McGowan BM, Stanley SA, White NE, Spangeus A, Patterson M, Thompson EL, Smith KL, Donovan J, Gardiner JV, Ghatei MA, et al. (2007) Hypothalamic mapping of orexigenic action and Fos-like immunoreactivity following relaxin-3 administration in male Wistar rats. Am J Physiol Endocrinol Metab 292:E913-919. (Pubitemid 46411072)
22. Osmond RI, Sheehan A, Borowicz R, Barnett E, Harvey G, Turner C, Brown A, Crouch MF, and Dyer AR (2005) GPCR screening via ERK 1/2: a novel platform for screening G protein-coupled receptors. J Biomol Screen 10:730-737. (Pubitemid 41476808)
23. Pearson G, English JM, White MA, and Cobb MH (2001) ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation. J Biol Chem 276:7927-7931. (Pubitemid 37385589)
24. Price MA, Cruzalegui FH, and Treisman R (1996) The p38 and ERK MAP kinase pathways cooperate to activate ternary complex factors and c-fos transcription in response to UV light. EMBO J 15:6552-6563.
25. Roux PP and Blenis J (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320-344.
26. Sexton PM, McKenzie JS, Mason RT, Moseley JM, Martin TJ, and Mendelsohn FA (1986) Localization of binding sites for calcitonin gene-related peptide in rat brain by in vitro autoradiography. Neuroscience 19:1235-1245. (Pubitemid 17217018)
27. Shahrestanifar M, Fan X, and Manning DR (1999) Lysophosphatidic acid activates NF-kappaB in fibroblasts. A requirement for multiple inputs. J Biol Chem 274: 3828-3833. (Pubitemid 29077232)
28. Shen CP, Tsimberg Y, Salvadore C, and Meller E (2004) Activation of Erk and JNK MAPK pathways by acute swim stress in rat brain regions. BMC Neurosci 5:36. (Pubitemid 40177045)
29. Sutton SW, Bonaventure P, Kuei C, Roland B, Chen J, Nepomuceno D, Lovenberg TW, and Liu C (2004) Distribution of G-protein-coupled receptor (GPCR)135 binding sites and receptor mRNA in the rat brain suggests a role for relaxin-3 in neuroendocrine and sensory processing. Neuroendocrinology 80:298-307. (Pubitemid 40470238)
30. Tanaka M, Iijima N, Miyamoto Y, Fukusumi S, Itoh Y, Ozawa H, and Ibata Y (2005) Neurons expressing relaxin 3/INSL 7 in the nucleus incertus respond to stress. Eur J Neurosci 21:1659-1670. (Pubitemid 40646611)
31. van der Westhuizen ET, Wade JD, Sexton PM, and Summers RJ (2009) Addition of a carboxy-terminal green fluorescent protein does not alter the binding and signaling properties of relaxin family peptide receptor 3. Ann NY Acad Sci 1160:105-107.
32. van der Westhuizen ET, Werry TD, Sexton PM, and Summers RJ (2007) The relaxin family peptide receptor 3 activates extracellular signal-regulated kinase 1/2 through a protein kinase C-dependent mechanism. Mol Pharmacol 71:1618-1629.
33. Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA, Wu W, Fahmy B, Olini GC, Davis JE, et al. (1999) RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 291:680-687. (Pubitemid 29503541)
34. Whitmarsh AJ and Davis RJ (1996) Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74:589-607.
35. Yuan J and Yankner BA (2000) Apoptosis in the nervous system. Nature 407:802-809.